Changsheng Bio-technology Co Ltd operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Changsheng Bio-technology Co Ltd with three other
companies in this sector in China:
Beijing Tiantan Biologic.
sales of 1.77 billion Chinese Renmimbi [US$279.43 million]
of which 86%
was Blood products),
Chongqing Zhifei Biological Products Co Ltd
(1.34 billion Chinese Renmimbi [US$212.53 million]
of which 96%
was Biological Product), and
Staidson (Beijing) Biopharmaceuticals Co Ltd
(1.39 billion Chinese Renmimbi [US$219.70 million]
of which 100%
was Pharmaceutical manufacturing).
During the year ended December of 2017, sales at
Changsheng Bio-technology Co Ltd were 1.55 billion Chinese Renmimbi (US$245.90 million).
increase of 52.6%
versus 2016, when the company's sales were 1.02 billion Chinese Renmimbi.
This was the third consecutive year of growth at Changsheng Bio-technology Co Ltd.
Sales of Others saw an increase
that was more than double the company's growth rate: sales were up
374.3% in 2017, from
2.94 million Chinese Renmimbi to 13.93 million Chinese Renmimbi.